Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of September 2020, with a specific reporting date of September 11, 2020. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| 2020-09-10 | Ordinary Shares (25p each) | £15.2035 | 160 shares (aggregated across 10 individuals) | London Stock Exchange (XLON) |
Note: The total volume represents the sum of acquisitions by 10 distinct executives, ranging from 16 to 18 shares per individual.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy. It reports routine compliance disclosures for share acquisitions made by senior management on a single date.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed as "Acquisition of Ordinary Shares under the Company's Share Reward Plan."
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares by senior executives, not sales.
- Participants: Transactions involved 10 individuals, including the CEO (Ms. E. Walmsley), President of Global Vaccines (Mr. R. Connor), and other SVPs and officers.
- Valuation: All shares were acquired at a uniform price of £15.2035 per share.
- Volume: Individual transaction volumes were minimal (16 or 18 shares per person), indicating standard participation in a share reward scheme rather than significant open-market trading.
- Financial Data: Investors should refer to GSK's Form 20-F or quarterly earnings releases for actual revenue, profit, and cash flow data, as this filing does not provide them.